KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Tax Provisions: 2016-2025

Historic Tax Provisions for BeOne Medicines (ONC) over the last 10 years, with Sep 2025 value amounting to $22.3 million.

  • BeOne Medicines' Tax Provisions fell 3.14% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.7 million, marking a year-over-year increase of 83.30%. This contributed to the annual value of $111.8 million for FY2024, which is 100.07% up from last year.
  • Latest data reveals that BeOne Medicines reported Tax Provisions of $22.3 million as of Q3 2025, which was up 326.91% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Tax Provisions ranged from a high of $66.5 million in Q4 2024 and a low of -$15.4 million during Q4 2021.
  • Moreover, its 3-year median value for Tax Provisions was $14.5 million (2024), whereas its average is $19.5 million.
  • Per our database at Business Quant, BeOne Medicines' Tax Provisions plummeted by 397.94% in 2021 and then surged by 3,639.57% in 2022.
  • BeOne Medicines' Tax Provisions (Quarterly) stood at -$15.4 million in 2021, then skyrocketed by 193.59% to $14.4 million in 2022, then increased by 16.78% to $16.8 million in 2023, then spiked by 296.46% to $66.5 million in 2024, then fell by 3.14% to $22.3 million in 2025.
  • Its Tax Provisions was $22.3 million in Q3 2025, compared to $5.2 million in Q2 2025 and $19.6 million in Q1 2025.